A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Trial Profile

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2017

At a glance

  • Drugs Sapanisertib (Primary) ; TAK 117 (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 10 May 2017 Planned End Date changed from 1 Jan 2019 to 30 Nov 2020.
    • 10 May 2017 Planned primary completion date changed from 1 May 2017 to 30 Mar 2018.
    • 02 Nov 2016 Planned End Date changed from 1 Aug 2019 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top